SCHEMBL18039013

SCHEMBL18039013

CCN(CC)S(=O)(=O)c1ccc(=O)n(CC(=O)c2ccc(-c3cccc(C(F)(F)F)c3)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ LMNA P02545 5/20 0.48
▸ NPSR1 Q6W5P4 4/20 0.48
▸ MAPT P10636 4/20 0.48
▸ HTT P42858 4/20 0.48
▸ GAA P10253 3/20 0.48
▸ XBP1 P17861 1/20 0.48
▸ PAX8 Q06710 1/20 0.48
▸ USP2 O75604 1/20 0.45
▸ PTGDR2 Q9Y5Y4 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ GPR55 Q9Y2T6 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038969 0.90 PTGDR2 (0.44) SMN1; SMN2LMNANPSR1MAPTHTT
SCHEMBL18038967 0.81 GAA (0.47) SMN1; SMN2LMNAMAPTHTTGAA
SCHEMBL30207105 0.81 GAA (0.47) SMN1; SMN2LMNAMAPTHTTGAA
SCHEMBL18039019 0.81 LMNA (0.53) SMN1; SMN2LMNAMAPTHTTGAA
SCHEMBL18054903 0.81 ALDH1A1 (0.45) SMN1; SMN2LMNANPSR1MAPTGAA
SCHEMBL18038998 0.81 GAA (0.46) SMN1; SMN2LMNAMAPTHTTGAA
SCHEMBL22051931 0.78 GAA (0.42) SMN1; SMN2LMNAMAPTHTTGAA
SCHEMBL22050486 0.76 USP5 (0.51) LMNAMAPTHTTGAAALDH1A1
SCHEMBL22051935 0.76 USP5 (0.51) LMNAMAPTHTTGAAALDH1A1
SCHEMBL22050495 0.73 GAA (0.44) SMN1; SMN2LMNAMAPTHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 SMN1; SMN2 2842/4885LMNA 3330/4885NPSR1 2475/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 SMN1; SMN2 2818/4885LMNA 3349/4885NPSR1 2408/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 SMN1; SMN2 2842/4885LMNA 3330/4885NPSR1 2475/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 SMN1; SMN2 2818/4885LMNA 3349/4885NPSR1 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback